Login
← Go Back
Suven Life Sciences
SUVEN · Pharma > Pharmaceuticals & Drugs · Chairman: Venkateswarlu Jasti Listing date: Oct. 23, 2003 · Employees: 130 · Hyderabad · http://www.suven.com
Stock Price vs Company Growth
1d
0.8%
1w
1.8%
1m
6.5%
3m
4.4%
6m
44.9%
1y
91.5%
5y
14.1%
10y
3.8%
all
8.2%
🤔 How to analyze this graph?
Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price
₹ 113 0.8%
94
122
Company Overview
Sales
11.9 Cr
Growth: -0.4%
Profit after Tax
-114 Cr
Growth: -7.6%
Small Cap
2,474 Cr
P/S: 207.6x
Industry P/S: 2.6x
Fundamentals
Sales (Cr) ₹ 11.9
Growth -0.4%
EBITDA -1084.3%
P/S 207.6x
Dividend 0.0%
P/E -23.8x
Book Value ₹ 13.3
PEG Ratio 62.6x
ROE -33.7%
P/B 8.6x
Shareholding Pattern
Institutions
Rambabu Chirumamilla
1.56 %
Iepf
0.14 %
Promoters
Jasti Property And Equity Holdings Private Limited(Initscapacityassoletrusteeofjastifamilytrust)
60.0 %
Others
Increase    Decrease    No change
Company Profile Detailed
Suven Life Sciences was promoted by Mrs. and Mr. Venkat Jasti in 1989, as a Private Limited Company. Later it was converted into a Public Limited Company in January 1995.Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets.
Belongs to (4 Indices)
Investors (36)
iepf
katkar.s...
finquest...
Followers (7)
yogesh
damerla
samir7